TY  - JOUR
T1  - An Overview of New Oral Anticoagulant Toxicity
AU  - Çelik, Kamuran
AU  - Elumar, Funda
PY  - 2024
DA  - December
Y2  - 2024
DO  - 10.51262/ejtox.1603887
JF  - Eurasian Journal of Toxicology
JO  - Eurasian J Tox
PB  - Acil Tıp Uzmanları Derneği
WT  - DergiPark
SN  - 2667-8675
SP  - 55
EP  - 58
VL  - 6
IS  - 3
LA  - en
AB  - Extended life expectancy, changes in dietary habits, and a sedentary lifestyle have contributed to an increased risk of stroke and myocardial infarction. Atherosclerosis and thrombosis are the underlying causes of stroke and myocardial infarction. Anticoagulants have a significant role in both the prevention and treatment of these conditions. The difficulty of monitoring warfarin derivatives, which have been in use until recently, and their narrow therapeutic range paved the way for the development and use of new oral anticoagulants. Rivaroxaban, Apixaban, Edoxaban, and Betrixaban are Factor Xa inhibitors, while Dabigatran is a Thrombin (FIIa) inhibitor, and together they comprise the new oral anticoagulants. It is crucial to manage any accidental or intentional overdose with these new oral anticoagulants. The present review focuses on the characteristics of novel anticoagulants and their toxicological management.
KW  - thrombosis
KW  - emergency
KW  - anticoagulant
KW  - stroke
CR  - Garcia D, Libby E, Crowther MA. The new oral
anticoagulants. Blood, 2010;115(1), 15–20. https://doi.
org/10.1182/blood-2009-09-241851
CR  - Atalan N. Hemostaz. GKD Anest Yoğ Bak Dern
Derg, 2013;19(3), 109-112. https://doi.org/10.5222/
GKDAD.2013.109.
CR  - Acar BA, Akpınar ÇK, Alioğlu Z, Arlıer Z, Arsava EM, Aytaç
E, et al. İnme klinik pratiğinde NOAK kullanımı: Türk Beyin
Damar Hastalıkları Derneği Uzman Görüşü. Türk Beyin
Damar Hastalıkları Dergisi 2020;26(3):190-235. https://doi.
org/10.5505/tbdhd.2020.26213
CR  - Stangier J. Clinical pharmacokinetics and pharmacodynamics of
the oral direct thrombin inhibitor dabigatran etexilate. Clinical
pharmacokinetics, 2008;47(5), 285–295. https://doi.
org/10.2165/00003088-200847050-00001
CR  - McBride L, Wang J, Ho P, Langsford D. Dabigatran Toxicity
in Acute Kidney Injury: Hemodialysis and Idarucizumab Required. Kidney international reports, 2008;4(3), 500–504. https://doi.org/10.1016/j.ekir.2018.11.015
Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S,
Bernstein RA, et al. Idarucizumab for Dabigatran Reversal
- Full Cohort Analysis. The New England journal of
medicine, 2017;377(5), 431–441. https://doi.org/10.1056/
NEJMoa1707278
CR  - Miller KM, Brenner MJ. Betrixaban for Extended
Venous Thromboembolism Prophylaxis in High-Risk
Hospitalized Patients: Putting the APEX Results into
Practice. Drugs, 2019;79(3), 291–302. https://doi.org/10.1007/
s40265-019-1059-y
CR  - Connolly SJ, Sharma M, Cohen AT, Demchuk AM,
Członkowska A, Lindgren AG, et al. Andexanet for Factor
Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. The
New England journal of medicine, 2024;390(19), 1745–1755.
https://doi.org/10.1056/NEJMoa2313040
CR  - Milling TJ, Middeldorp S, Xu L, Koch B, Demchuk
A, Eikelboom JW, et al. Final Study Report of
Andexanet Alfa for Major Bleeding With Factor Xa
Inhibitors. Circulation, 2023;147(13),1026–1038. https://doi.
org/10.1161/CIRCULATIONAHA.121.057844
CR  - Dobesh PP, Fermann GJ, Christoph MJ, Koch B, Lesén
E, Chen H, et al. Lower mortality with andexanet alfa vs
4-factor prothrombin complex concentrate for factor Xa
inhibitor-related major bleeding in a U.S. hospital-based
observational study. Research and practice in thrombosis and
haemostasis, 2023;7(6), 102192. https://doi.org/10.1016/j.
rpth.2023.102192
CR  - Neumann MA, Sieg N, Garcia Borrega J, Hüser C, Caspers
M, Shimabukuro-Vornhagen A, et al. Überdosierung von
direkten oralen Antikoagulanzien [Overdosing of direct oral
anticoagulants]. Medizinische Klinik, Intensivmedizin und
Notfallmedizin, 2024;10.1007/s00063-024-01154-8. Advance
online publication. https://doi.org/10.1007/s00063-024-01154-
8
CR  - Boissier E, Senage T, Babuty A, Gouin-Thibault I, Rozec
B, Roussel JC, et al. Heparin Anti-Xa Activity, a Readily
Available Unique Test to Quantify Apixaban, Rivaroxaban,
Fondaparinux, and Danaparoid Levels. Anesthesia and
analgesia, 2021;132(3), 707–716. https://doi.org/10.1213/
ANE.0000000000005114
CR  - Bonanno FG. Management of Hemorrhagic Shock:
Physiology Approach, Timing and Strategies. Journal of
clinical medicine, 2022;12(1),260. https://doi.org/10.3390/
jcm12010260
CR  - Galvagno SM, Nahmias JT, Young DA. Advanced Trauma
Life Support Update 2019: Management and Applications
for Adults and Special Populations. Anesthesiology
clinics, 2019;37(1),13–32. https://doi.org/10.1016/j.
anclin.2018.09.009
Trauma and severe bleeding. Tranexamic acid within one hour
to reduce mortality. Prescrire international, 2013;22(140),
189–190.
UR  - https://doi.org/10.51262/ejtox.1603887
L1  - https://dergipark.org.tr/en/download/article-file/4451449
ER  -